Lavelle Erin M. 4
4 · Neoleukin Therapeutics, Inc. · Filed May 13, 2021
Insider Transaction Report
Form 4
Lavelle Erin M.
Director
Transactions
- Award
Stock Option (Right to Buy)
2021-05-11+25,000→ 25,000 totalExercise: $11.40Exp: 2031-05-10→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.